Fatty Liver Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Accordingly, activators of Nrf2 have been implicated as promising therapeutic targets for the treatment of NASH.
|
31035006 |
2019 |
Fatty Liver Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Sulforaphane and its precursor glucoraphanin are derived from broccoli sprouts and are the most potent natural Nrf2 inducers-they may protect mitochondrial function, thus suppressing the development of NASH.
|
31775341 |
2019 |
Fatty Liver Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results simultaneously confirmed that ICAB had a significant protective effect on fibrosis in NASH by inhibiting oxidative stress via Nrf2 and suppressing multiple profibrogenic factors through miR-122/HIF-1α signalling pathway.
|
30180301 |
2019 |
Fatty Liver Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Hepatocellular iNOS protects liver from NASH through Nrf2-dependent activation of HO-1.
|
31043271 |
2019 |
Fatty Liver Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Silibinin can ameliorate some metabolic alterations and induce some molecular changes by activating the CFLAR-JNK pathway and thereby regulating its downstream target genes involved in lipid metabolism (PPARα, SREBP-1C and PNPLA3), glucose uptake (PI3K-AKT), oxidative stress (NRF2, CYP2E1, CYP4A) and inflammatory response(NO) in OA-treated HepG2 cells demonstrating its possible use in ameliorating various symptoms of NASH.
|
30248539 |
2018 |
Fatty Liver Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The pathogenetic mechanism (s) underlying the NASH development was investigated in p62:Nrf2 double-knockout (DKO) mice.
|
29276215 |
2018 |
Fatty Liver Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
By regulating expression of Nrf2 and other related factors, TFHL may play a role in antioxidative stress and prevention of NASH.
|
26919834 |
2018 |
Fatty Liver Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The effect was related to alteration of lipid metabolism-related gene expression, activation of the Nrf2 pathway and inhibition of the NF-κB signaling pathway in the NASH liver.
|
30191499 |
2018 |
Fatty Liver Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Lansoprazole also increased the expression of Nrf2, but not HO-1, in the liver of NASH model rats.
|
29355950 |
2018 |
Fatty Liver Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Thus, we hypothesize an amplifying loop among lipogenesis, palmitate, Nrf2 and Nlrp3 that leads to a higher risk of NAFLD progression to NASH in a high-fructose diet compared to a high-saturated fat intake.
|
28189916 |
2017 |
Fatty Liver Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These findings suggest that CKS reduces HFD-induced NASH by up-regulation of Nrf2-mediated anti-oxidant enzymes and PPARα-regulated fatty acid oxidation.
|
27984800 |
2017 |
Fatty Liver Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Nrf2 deficiency exacerbates NASH whereas anti-inflammatory and hypolipidemic activities of GTE likely occur largely independent of Nrf2 signaling.
|
26679056 |
2016 |
Fatty Liver Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In addition, we identified that the hepatic mRNA levels of Nrf2 target genes such as Nqo-1 and GSTA-1 were significantly increased in NASH patients.
|
27634173 |
2016 |
Fatty Liver Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, our findings lead to the hypothesis that oxidative stress may enhance Nrf2 activation in the livers of patients with NASH.
|
23822105 |
2014 |
Fatty Liver Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
As the cytosolic repressor kelch-like ECH-associated protein 1 (Keap1) negatively regulates Nrf2, activation of Nrf2 facilitated by its release from Keap1 may represent a promising strategy in the treatment of NASH.
|
23592516 |
2013 |